See more : Celsius Resources Limited (CLA.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Exicure, Inc. (XCUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exicure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Applied UV, Inc. (AUVIP) Income Statement Analysis – Financial Results
- Sumavision Technologies Co.,Ltd. (300079.SZ) Income Statement Analysis – Financial Results
- Ad-Sol Nissin Corporation (3837.T) Income Statement Analysis – Financial Results
- Gurit Holding AG (GUR.SW) Income Statement Analysis – Financial Results
- Golden Ridge Resources Ltd. (GORIF) Income Statement Analysis – Financial Results
Exicure, Inc. (XCUR)
About Exicure, Inc.
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 28.83M | -483.00K | 16.61M | 1.30M | 118.00K | 9.72M | 1.04M | 2.39M |
| Cost of Revenue | 920.00K | 1.86M | 1.78M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| Gross Profit | -1.42M | 26.97M | -2.26M | -15.48M | -18.04M | -14.00M | -3.36M | -12.62M | -7.74M |
| Gross Profit Ratio | 0.00% | 93.56% | 468.32% | -93.19% | -1,392.28% | -11,865.25% | -34.58% | -1,218.44% | -323.95% |
| Research & Development | 1.42M | 19.77M | 48.98M | 32.09M | 19.34M | 14.12M | 13.08M | 13.66M | 10.12M |
| General & Administrative | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -133.00K |
| SG&A | 12.65M | 10.89M | 13.09M | 9.96M | 8.57M | 7.82M | 7.05M | 3.54M | 5.28M |
| Other Expenses | 0.00 | -40.00K | -11.00K | 322.00K | 379.00K | -249.00K | 191.00K | -55.00K | 0.00 |
| Operating Expenses | 14.08M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.40M |
| Cost & Expenses | 15.00M | 30.66M | 62.07M | 42.05M | 27.91M | 21.94M | 20.13M | 17.20M | 15.53M |
| Interest Income | 32.00K | 15.00K | 141.00K | 972.00K | 178.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 595.00K | 1.69M | 573.00K | 786.00K | 672.00K | 795.00K | 724.00K | 0.00 |
| Depreciation & Amortization | 1.38M | 1.86M | 1.78M | 1.45M | 724.00K | 358.00K | 232.00K | 180.00K | 133.00K |
| EBITDA | -15.54M | 78.00K | -60.63M | -22.65M | -24.79M | -21.38M | -9.98M | -16.04M | -13.02M |
| EBITDA Ratio | 0.00% | -1.93% | 12,554.87% | -136.61% | -1,954.94% | -18,394.92% | -102.73% | -1,547.97% | -544.85% |
| Operating Income | -15.00M | -1.83M | -62.55M | -25.44M | -26.62M | -21.82M | -10.41M | -16.16M | -13.14M |
| Operating Income Ratio | 0.00% | -6.35% | 12,950.10% | -153.11% | -2,053.78% | -18,490.68% | -107.08% | -1,560.04% | -550.42% |
| Total Other Income/Expenses | -1.92M | -542.00K | -1.55M | 768.00K | 314.00K | -594.00K | -604.00K | -779.00K | -7.00K |
| Income Before Tax | -16.91M | -2.37M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Income Before Tax Ratio | 0.00% | -8.23% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| Income Tax Expense | 0.00 | 209.00K | 1.68M | 895.00K | 1.17M | 423.00K | 986.00K | 669.00K | 0.00 |
| Net Income | -16.91M | -2.58M | -64.10M | -24.67M | -26.30M | -22.41M | -11.01M | -16.94M | -13.15M |
| Net Income Ratio | 0.00% | -8.96% | 13,271.64% | -148.49% | -2,029.55% | -18,994.07% | -113.29% | -1,635.23% | -550.71% |
| EPS | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.93 | -10.04 |
| EPS Diluted | -2.11 | -0.56 | -21.70 | -8.49 | -13.68 | -16.32 | -8.37 | -12.88 | -10.04 |
| Weighted Avg Shares Out | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.31M | 1.31M |
| Weighted Avg Shares Out (Dil) | 8.01M | 4.62M | 2.95M | 2.91M | 1.92M | 1.37M | 1.32M | 1.32M | 1.31M |
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company's failure to timely...
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered...
Why Is Exicure (XCUR) Stock Up 57% Today?
Exicure (NASDAQ: XCUR ) stock is rising higher on Friday despite a lack of news from the early-stage biotechnology company. Exicure hasn't released any recent press releases or made any filings that would result in today's stock rally.
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company's failure to timely...
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.
3 Nano-Cap Penny Stocks to Buy for Explosive Gains in 2023
Nano-cap penny stocks are arguably the most volatile and speculative investments you can make other than nano-cap cryptos. Shares of these small businesses generally have a market capitalization lower than $50 million.
Penny Stocks To Buy: 6 Insider Picks Before 2023
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Top Penny Stocks To Buy According To Insiders Before 2023
Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Exicure (XCUR) Stock: 1-For-30 Reverse Split Goes Into Effect
A reverse stock split of Exicure, Inc. (NASDAQ: XCUR) of 1-for-30 has gone into effect. These are the details.
Source: https://incomestatements.info
Category: Stock Reports